We are monitoring the impact of COVID-19 on Asia Pacific Checkpoint Inhibitors Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 2087
Share on
Share on

Asia Pacific Checkpoint Inhibitors Market Research Report – Segmented By Type, Application & By Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, Forecast, Growth | 2019 - 2024

Pulished: February, 2020
ID: 2087
Pages: 145

Asia Pacific Checkpoint Inhibitors Market Size & Growth (2019 – 2024):

The Size of the Asia Pacific Checkpoint Inhibitors Market is valued at USD 2.01 billion in 2019 and is projected to reach USD 7.41 billion by 2024, growing at a CAGR of 29.8% during the forecast period from 2019 to 2024.

The immune system uses checkpoints to avoid the overactivation of the immune system on normal cells. Cancer cells use these checkpoints to escape the immune system by arraying with normal cells. Checkpoint inhibitors are drugs that block these normal cells and let the immune system attack cancer cells. This is one of the treatments available in Immunotherapy.

Rising Prevalence of cancer globally, and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the market. However, the high expense involved in R&D activities is one of the major factors restricting the growth of the market.

CTLA-4 Segment holds the highest share accounting for almost 94 % of the overall market. However, this segment is expected to lose some of its markets to the PD-1 inhibitors segment during the forecast period as the majority of new treatments are based on PD-1 inhibitors.

Asia Pacific Checkpoint Inhibitors Market has been segmented and sub-segmented into the following categories

  • By Drug: PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others.
  • By Application: Lung cancer, Renal cancer, Blood cancer, Bladder Cancer, Hodgkin lymphoma, Melanoma, Others.
  • By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC.

On the basis of region, Asia-Pacific is the fastest-growing region because of the collaborations of international players with companies in this region.

Key Market Companies leading the Asia Pacific Checkpoint Inhibitors Market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma

1.Introduction                                                                  

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                          

                1.4 General Study Assumptions                                                

2. Research Methodology                                                                           

                2.1 Introduction                                                               

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                           

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                      

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

3. Overview                                                                       

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 Epidemology                                                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                    

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                                              

5. Market Segmentation                                                                              

                5.1 Drug Type                                                   

                                5.1.1 Introduction                                           

                                5.1.2 PD-1 inhibitors                                       

                                5.1.3 PD-L1 inhibitors                                     

                                5.1.4 CTLA-4                                      

                                5.1.5  Chimeric Antigen Receptor T-cell                                 

                                5.1.6  Others                                     

                                5.1.7 Y-o-Y Growth Analysis, By Drug Type                                           

                                5.1.8 Market Attractiveness Analysis, By Drug Type                                         

                                5.1.9 Market Share Analysis, By Drug Type                                          

                5.2 Application                                                 

                                5.2.1 Introduction                                           

                                5.2.2 Lung cancer                                            

                                5.2.3 Renal cancer                                           

                                5.2.4 Blood cancer                                          

                                5.2.5 Bladder Cancer                                      

                                5.2.6  Hodgkin lymphoma                                            

                                5.2.7 Melanoma                                              

                                5.2.8  Others                                     

                                5.2.9 Y-o-Y Growth Analysis, By Application                                         

                                5.2.10  Market Attractiveness Analysis, By Application                                   

                                5.2.11  Market Share Analysis, By Application                                     

6. Geographical Analysis                                                                              

                6.1 Introduction                                                               

                                6.1.1 Regional Trends                                    

                                6.1.2 Impact Analysis                                     

                                6.1.3 Y-o-Y Growth Analysis                                        

                                                6.1.3.1 By Geographical Area                     

                                                6.1.3.2 By Drug Type                      

                                                6.1.3.3 By Application                    

                                6.1.4  Market Attractiveness Analysis                                     

                                                6.1.4.1 By Geographical Area                     

                                                6.1.4.2 By Drug Type                      

                                                6.1.4.3 By Application                    

                                6.1.5  Market Share Analysis                                      

                                                6.1.5.1 By Geographical Area                     

                                                6.1.5.2 By Drug Type                      

                                                6.1.5.3 By Application                    

                6.2 China                                                             

                6.3 India                                                              

                6.4 Japan                                                            

                6.5 South Korea                                                               

                6.6 Australia                                                      

7.Strategic Analysis                                                                        

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                       

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                                              

                                7.2.5 Competitive Rivalry within the Industry                                     

8.Market Leaders' Analysis                                                                         

                8.1 Merck & Co., Inc.                                                     

                                8.1.1 Overview                                 

                                8.1.2 Product Analysis                                   

                                8.1.3 Financial analysis                                  

                                8.1.4 Recent Developments                                       

                                8.1.5 SWOT analysis                                       

                                8.1.6 Analyst View                                          

                8.2 Bristol-Myers Squibb                                                              

                8.3 Roche                                                           

                8.4 AstraZeneca                                                               

                8.5 Ono Pharmaceutical Co., Ltd.                                                              

                8.6  Juno Therapeutics                                                  

                8.7 Novartis International AG                                                    

                8.8 Kite Pharma                                                               

9.Competitive Landscape                                                                            

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                         

                9.4 New Product Launches                                                         

10.Market Outlook and Investment Opportunities                                                                          

Appendix                                                                           

                a) List of Tables                                                

                b) List of Figures                                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  2. Asia-Pacific PD-1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  3. Asia-Pacific PD-L1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  4. Asia-Pacific CTLA-4 Market By Region, From 2019-2024 ( USD Billion )
  5. Asia-Pacific Chimeric Antigen Receptor T-cell Market By Region, From 2019-2024 ( USD Billion )
  6. Asia-Pacific Others Market By Region, From 2019-2024 ( USD Billion )
  7. Asia-Pacific Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  8. Asia-Pacific Lung cancer Market By Region, From 2019-2024 ( USD Billion )
  9. Asia-Pacific Renal cancer Market By Region, From 2019-2024 ( USD Billion )
  10. Asia-Pacific Blood cancer Market By Region, From 2019-2024 ( USD Billion )
  11. Asia-Pacific Bladder Cancer Market By Region, From 2019-2024 ( USD Billion )
  12. Asia-Pacific Hodgkin lymphoma Market By Region, From 2019-2024 ( USD Billion )
  13. Asia-Pacific Melanoma Market By Region, From 2019-2024 ( USD Billion )
  14. Asia-Pacific Others Market By Region, From 2019-2024 ( USD Billion )
  15. Japan Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  16. Japan Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  17. China Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  18. China Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  19. India Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  20. India Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  21. Australia Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  22. Australia Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  23. South Korea Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  24. South Korea Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample